logo
  

Amgen: FDA To Review SNDA For Otezla - Quick Facts

Amgen (AMGN) announced the FDA has accepted for review the supplemental New Drug Application for Otezla for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The PDUFA action date is December 19, 2021.

David Reese, executive vice president of Research and Development at Amgen, said: "The FDA's acceptance of this sNDA for Otezla is a significant milestone toward achieving our goal of potentially providing the first and only oral treatment option for the underserved mild-to-moderate patient population."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Viona Pharmaceuticals Inc. has recalled type 2 diabetes drug Metformin in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Ford Motor Co. on Monday issued a recall for a total of 19,626 2021 F-Series Super Duty vehicles with dual rear wheels in North America. These include 17,616 vehicles in the U.S. and federal territories; 1,779 in Canada; and 231 in Mexico. The affected vehicles are equipped with front-wheel hub extenders... Royal Philips has recalled specific sleep and respiratory care devices due to the potential health risks related to the polyester-based polyurethane or PE-PUR sound abatement foam component. The affected products include Bi-Level Positive Airway Pressure or Bi-Level PAP, Continuous Positive Airway Pressure or CPAP, and mechanical ventilator devices.
Follow RTT